Infusion authorization
Secure approval before scheduling, with the exact drug, dose and administration codes that will be billed.
Rheumatology | Texas
In rheumatology the drug is usually worth more than the visit. T Zync protects the infusion suite: authorization before the chair is booked, drug units that match the NDC, and underpayment review against the contracted rate.
01 Why rheumatology is different
A rheumatology practice that purchases biologics and bills them after administration is financing the drug. When an infusion is given against an expired authorization, or billed with units that do not match the NDC, the denial is not a delayed payment. It is a loss equal to the acquisition cost of the drug.
The second exposure is quieter. Biologics are reimbursed against payer-specific contracted rates, and underpayments on high-cost drugs are easy to miss because the claim technically paid. Without line-level rate comparison, the shortfall is absorbed silently, month after month.
T Zync manages both: authorization and reauthorization before the chair is booked, and payment validation against the contracted rate after it is billed.
02 What we handle
Secure approval before scheduling, with the exact drug, dose and administration codes that will be billed.
Calendar approval expiry and remaining units so no patient is infused on a lapsed approval.
Bill the J-code and administration codes together, with units reconciled to the NDC and dose given.
Apply discarded-drug and single-dose container modifiers as payers require.
Bill the specific biosimilar dispensed, and track payer preference policies that change which product is covered.
Code aspiration and injection procedures with correct guidance rules and bundling awareness.
Compare biologic payments line by line against contracted rates rather than accepting a paid status.
Work authorization, unit and policy denials against filing deadlines before they become unrecoverable.
03 Codes that carry rheumatology revenue
Rheumatology billing concentrates in the infusion suite, where code accuracy and drug units carry the most financial weight.
| Code family | What it covers |
|---|---|
| 96365, 96366 | Intravenous infusion for therapy or diagnosis, initial hour and each additional hour. |
| 96413, 96415 | Infusion administration for agents payers classify as complex, initial hour and each additional hour. |
| 96372 | Therapeutic or diagnostic injection, subcutaneous or intramuscular. |
| J1745 and its biosimilars | Infliximab and the biosimilar products billed under their own HCPCS codes, where the product dispensed must match the code billed. |
| J0129, J3262, J1602 | Abatacept, tocilizumab and intravenous golimumab, each with their own unit definitions. |
| J9312, J0490, J2507 | Rituximab, belimumab and pegloticase, all high-cost agents where unit errors are expensive. |
| JW and JZ modifiers | Discarded drug reporting and the attestation that no amount was discarded from a single-dose container. |
| 20600–20611 | Arthrocentesis, aspiration and injection of small, intermediate and major joints, with and without ultrasound guidance. |
| 77080, 86200, 86431, 86038 | Bone density study and the serology commonly ordered alongside rheumatology evaluation and monitoring. |
Codes listed reflect common documentation scenarios in this specialty and are shown for orientation. Correct code selection always depends on the documentation, the payer's policy and the current code set for the year of service. T Zync verifies current payer policy at the time of billing.
04 How it runs
Confirm approval, units and expiry against the exact codes to be billed before scheduling.
Record dose, units and wastage at the point of administration, not from memory afterwards.
Submit drug and administration codes together with NDC-matched units and required modifiers.
Compare payment against the contracted rate and pursue underpayments as actively as denials.
05 Texas payer landscape
In rheumatology a missed deadline is not a lost visit fee, it is the acquisition cost of a biologic. These are the rules that decide whether a balance is still recoverable.
| Payer or rule | What it means for your claims |
|---|---|
| Medicare – Novitas Solutions (Jurisdiction H) | The Part B contractor for Texas. Claims carry a twelve-month timely filing limit from the date of service, and a redetermination must be requested within 120 days of the initial determination notice. |
| Texas Medicaid (TMHP) | Fee-for-service claims must be filed within 95 days of the date of service, one of the shortest limits in the country and a frequent cause of unrecoverable Texas denials. |
| Medicaid managed care (STAR, STAR+PLUS) | Each managed care plan applies its own filing, authorization and appeal rules on top of state policy, so payer-specific edits matter more than a single Medicaid workflow. |
| Texas prompt pay | State-regulated HMO and PPO plans carry statutory deadlines for paying clean claims, which gives a documented clean submission real leverage in follow-up. |
| Commercial and Medicare Advantage | Filing limits are contract-specific and commonly range from 90 to 180 days, so the follow-up calendar should be driven by the contract rather than by habit. |
| Drug claims and appeal windows | High-cost drug denials carry the same appeal deadlines as any other claim, but far greater value per claim, which is why infusion denials are worked first rather than by age. |
Filing limits and appeal windows are set by payer policy and by contract, and they change. T Zync verifies the applicable deadline per payer at the time of work.
FAQ Rheumatology billing guidance
For guidance specific to your specialty, payer mix and systems, speak with T Zync.
Usually because something on the claim does not match the approval. Common causes are a different administration code than the one approved, drug units that do not reconcile to the NDC and dose, a lapsed approval date, or a biosimilar dispensed under a payer policy that prefers a different product.
Texas law requires state-regulated health plans to exempt a physician from prior authorization for a service when the physician's approval rate for that service is consistently high over the evaluation period. It applies to state-regulated plans, not to self-funded ERISA plans or Traditional Medicare, so exemption status has to be tracked per plan.
When a single-dose container is used and no amount was discarded, payers require the attestation modifier on the claim. Discarded amounts are reported separately. Missing this reporting is a frequent and entirely avoidable denial in infusion practices.
Yes. Approval expiry and remaining units are calendared per patient, and renewals are started before the current approval lapses, since an infusion given on a lapsed approval is generally unrecoverable.
By comparing each drug line against the payer's contracted rate rather than treating a paid claim as a closed claim. On high-cost agents, a small per-unit shortfall becomes a significant annual loss.
Yes. Payer policies that redirect the drug supply or mandate a specific biosimilar are tracked per plan, since they change both the authorization path and what the practice may bill.
06 Keep exploring
Approvals secured before the visit, with reauthorization tracking.
Specialty-aware ICD-10, CPT and HCPCS coding with documentation alignment.
ESRD monthly capitation, dialysis rounding and CKD office care.
Start with clarity